---
title: 'Series 3: Regulatory statistics'
author: "Giusi Moffa"
date: '2017-11-24'
image: "jclub/img/nakedEmperor.jpg"
description: Figure from abovethelaw.com
output:
  html_document: default
  pdf_document: default
draft: false
type: "post"
bibliography: jclub.bib
---

_[Figure from abovethelaw.com](https://abovethelaw.com/2017/10/when-the-emperor-has-no-clothes-3-tips-to-avoid-inadvertent-naked-licenses-under-trademark-law/)_ 

<!-- November 2nd 2017 -->

```{r buildSchedule, include=FALSE}
library(knitr)
library(kableExtra)
library(readr)
setwd("~/jData/jLibellus/entryFiles/websiteSource_juicy/content/jclub")
schedule <- read_csv("schedule.csv")
```

```{r displaySchedule, echo=FALSE}
kable(schedule, "html") %>% column_spec(c(1:2), width = "6em") %>% column_spec(c(1:2), width = "12em")
```
  
&nbsp;

_Following up on the 2nd EFSPI Workshop on Regulatory Statistics, on October 5-6th 2017 in Basel_

#### Regulatory guidelines around multiple endpoints

* [Multiple Endpoints in Clinical Trials: FDA Issues Draft Guidance](https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm536750.pdf)  
* [Announcement on RAPS (Regulatory Affairs Professionals Society )](http://raps.org/Regulatory-Focus/News/2017/01/12/26574/Multiple-Endpoints-in-Clinical-Trials-FDA-Issues-Draft-Guidance/)  
* [EMA Guideline on multiplicity issues in clinical trials Draft](http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2017/03/WC500224998.pdf)

&nbsp;

#### Update of the ICH E9 to include the concept and semantics of estimands
* [ICH E9 Addendum](http://www.ich.org/ichnews/newsroom/read/article/ich-e9r1-revised-guideline-reaches-step-2b-of-the-ich-process.html)
* [Per-Protocol Analyses of Pragmatic Trials](http://www.nejm.org/doi/full/10.1056/NEJMsm1605385?query=featured_clinical-trials)  
Miguel A. Hern√°n and James M. Robins  
Statistics in Medicine, 2017
* [Estimands and Their Role in Clinical Trials](http://www.tandfonline.com/doi/full/10.1080/19466315.2017.1302358?af=R)  
Mouna Akacha, Frank Bretz, David Ohlssen, Gerd Rosenkranz & Heinz Schmidli  
Statistics in Biopharmaceutical Research, 2017  
* [A taxonomy of estimands for regulatory clinical trials with discontinuations](http://onlinelibrary.wiley.com/doi/10.1002/sim.6841/full)  
Thomas Permutt  
Statistics in Medicine, 2015  
* [Estimands in clinical trials broadening the perspective](http://onlinelibrary.wiley.com/doi/10.1002/sim.7033/full) [[pdf]](http://onlinelibrary.wiley.com/doi/10.1002/sim.7033/pdf)  
with _Comments on Estimands in clinical trials broadening the perspective_ by  
[Thomas Permutt](http://onlinelibrary.wiley.com/doi/10.1002/sim.7160/full) [[pdf]](http://onlinelibrary.wiley.com/doi/10.1002/sim.7160/epdf)  
[Peter Bauer](http://onlinelibrary.wiley.com/doi/10.1002/sim.7162/full) [[pdf]](http://onlinelibrary.wiley.com/doi/10.1002/sim.7162/epdf)  
[Frank Rockhold](http://onlinelibrary.wiley.com/doi/10.1002/sim.7164/full)
[[pdf]](http://onlinelibrary.wiley.com/doi/10.1002/sim.7164/epdf)  
* [Editorial: Estimands in clinical trials - a challenge to intention to treat?](http://onlinelibrary.wiley.com/doi/10.1002/sim.7163/full)  
[[pdf]](http://onlinelibrary.wiley.com/doi/10.1002/sim.7163/epdf)  
Simon Day, 2016

<!-- * [Cytel - Estimands 101: Interview with Mouna Akacha](http://www.cytel.com/blog/estimands-101) -->